Takeda Enters 3-Year IBD Research Partnership with University of Chicago and Mount Sinai

Takeda Enters 3-Year IBD Research Partnership with University of Chicago and Mount Sinai
Takeda Pharmaceuticals U.S.A. announced that it has entered into a three-year partnership with two academic centers to further inflammatory bowel disease (IBD) research and patient care. The centers, The University of Chicago and the Icahn School of Medicine at Mount Sinai in New York, will advance research into IBD, and Takeda will translate scientific findings into new treatments and patient-focused support. The initiatives will focus on IBD and immunology (Mount Sinai), and IBD and digital innovation (University of Chicago). "Creating strong partnerships with the potential to discover game changing technologies and health solutions is a key priority for our company," Charlie Baum, MD, Takeda’s vice president and head of U.S. Medical and Scientific Affairs, said in a press release. "This research assures continued scientific focus and exploration to help people affected by IBD, a chronic, challenging to treat disease that impacts as many as 1.6 million Americans and 5 million people globally." Mount Sinai's work into immunology will focus on investigational approaches to lymphocytic homing to the colon and the effect of the microbiome on homing to the colon, and exploring therapeutic cell-based procedures to suppress intestinal inflammation. "A partnership between Takeda and Mount Sinai could lead to identifying novel homing markers to the large bowel and define innovative therapeutic targets in patients with IBD," sa
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *